Quality of compensation and well-being of patients with primary hypothyroidism and obesity
https://doi.org/10.14341/ket2016228-32
Abstract
Aim. The aim of the study was to compare quality of hypothyroidism compensation and well-being of patients with hypothyroidism with normal weight, overweight and obesity.
Methods. 306 patients with hypothyroidism on replacement therapy with L-T4 were included; of those 218 patients with compensated hypothyroidism. All patients were divided into groups depending on their body mass index: with normal body weight, overweight, obesity I and obesity II - III degree. We calculated the ideal body weight (IdBW) by Devine formula. Evaluation at baseline included: height, weight, BMI, quality of life (SF-36), TSQ, TSH, freeT3 (fT3), freeT4 (fT4) levels.
Results
There were no difference in the quality of compensation between groups of normal-weight, overweight and obese patients (p > 0,05). L-T4 dose in patients with obesity and overweight was significantly higher compared to normal-weight patients (p < 0,05). The L-T4 dose per 1 kg of actual body weight was significantly higher (p <0,001) in the normal-weight and overweight euthyroid patients compared to patients with obesity. In contrast, L-T4 dose per 1 kg of ideal body weight was significantly higher (p <0,001) in overweight (1.78 [1.52, 2.06]) and obese patients (1 9 [1.71, 2.4] 1.99 [1.72, 2.4]), as compared with normal-weight patients (1.49 [1.27, 1.78]). There were no correlation between the fT3, fT4 levels and weight, and also between the L-T4 dose and weight. QOL and TSQ levels were the same in the groups of normal-weight, overweight and obese patients (p>0,05).
Conclusions
The compensation of hypothyroidism in patients with overweight/obesity is not worse than that of normal-weight patients. The achievement of euthyroidism requires less L-T4 dose per 1 kg of the actual weight and significantly higher dose for 1 kg of ideal weight in obesity/overweight patients.
Keywords
About the Authors
Valentin V. FadeyevRussian Federation
MD, PhD, professor
Competing Interests: No conflict of interest
Tatyana Borisovna Morgunova
Russian Federation
MD, PhD, assistant professor
Competing Interests: No conflict of interest
Yulia Aleksandrovna Manuylova
Russian Federation
MD, PhD
Competing Interests: No conflict of interest
Meruert S. Madiyarova
Russian Federation
MD, PhD
Competing Interests: No conflict of interest
References
1. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid.2014;24(12):1670-1751. doi: 10.1089/thy.2014.0028.
2. Devdhar M, Drooger R, Pehlivanova M, et al. Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid. 2011;21(8):821-827. doi: 10.1089/thy.2011.0029.
3. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-127. doi: 10.1210/jc.2004-1306.
4. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med. 2000; 160(4):526. doi: 10.1001/archinte.160.4.526.
5. Diez JJ. Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J Gerontol A Biol Sci Med Sci. 2002;57(5):M315-320. doi: 10.1093/gerona/57.5.M315.
6. Leese GP, Jung RT, Scott A, et al. Long term follow-up of treated hyperthyroid and hypothyroid patients. Health Bull (Edinb). 1993;51(3):177-183.
7. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf). 1991;34(1):77-83.doi: 10.1111/j.1365-2265.1991.tb01739.x.
8. Michalaki MA, Gkotsina MI, Mamali I, et al. Impaired pharmacokinetics of levothyroxine in severely obese volunteers. Thyroid. 2011;21(5):477-481. doi: 10.1089/thy.2010.0149.
9. Yan LL, Daviglus ML, Liu K, et al. BMI and health-related quality of life in adults 65 years and older. Obes Res. 2004;12(1):69-76. doi: 10.1038/oby.2004.10.
10. Nigatu YT, Reijneveld SA, de Jonge P, et al. The combined effects of obesity, abdominal obesity and major depression/anxiety on health-related quality of life: the LifeLines cohort study. PLoSOne. 2016;11(2):e0148871. doi: 10.1371/journal.pone.0148871.
11. Zhu Y-B, Luo X-X, Wang Q. Study on the relationship between body mass index and health-related quality of life in middle-aged or older Chinese adults. Zhonghua liu xing bing xue za zhi =Zhonghua liuxingbingxue zazhi. 2009;30(7):687-691.
Review
For citations:
Fadeyev V.V., Morgunova T.B., Manuylova Yu.A., Madiyarova M.S. Quality of compensation and well-being of patients with primary hypothyroidism and obesity. Clinical and experimental thyroidology. 2016;12(2):28-32. (In Russ.) https://doi.org/10.14341/ket2016228-32

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).